Eesti - eesti - Ravimiamet

aurobindo pharma (malta) limited - olansapiin - tablett - 10mg 70tk; 10mg 35tk; 10mg 30tk; 10mg 96tk; 10mg 50tk; 10mg 7tk; 10mg 100tk; 10mg 56tk

Eesti - eesti - Ravimiamet

aurobindo pharma (malta) limited - olansapiin - suus dispergeeruv tablett - 10mg 14tk; 10mg 30tk; 10mg 70tk; 10mg 28tk; 10mg 100tk; 10mg 35tk; 10mg 10tk; 10mg 60tk; 10mg 1tk

Eesti - eesti - Ravimiamet

alembic pharmaceuticals europe limited - duloksetiin - gastroresistentne kõvakapsel - 30mg 28tk; 30mg 50tk; 30mg 14tk; 30mg 7tk; 30mg 98tk; 30mg 30tk

Eesti - eesti - Ravimiamet

pharmaswiss ceska republika s.r.o. - duloksetiin - gastroresistentne kõvakapsel - 40mg 28tk

Eesti - eesti - Ravimiamet

pharmaswiss ceska republika s.r.o. - duloksetiin - gastroresistentne kõvakapsel - 20mg 28tk

Eesti - eesti - Adama

adama - vees dispergeeruvad graanulid - tribenuroon-metüül - herbitsiidid

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - atezolüsumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastilised ained - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Eesti - eesti - Ravimiamet

accord healthcare b.v. - duloksetiin - gastroresistentne kõvakapsel - 60mg 98tk; 60mg 14tk; 60mg 30tk; 60mg 90tk; 60mg 10tk

Eesti - eesti - Ravimiamet

norbrook laboratories (ireland) limited - fiproniil+metopreen - täpilahus - 134mg+120,6mg 1.34ml 1.34ml 8tk; 134mg+120,6mg 1.34ml 1.34ml 2tk; 134mg+120,6mg 1.34ml 1.34ml 30tk; 134mg+120,6mg 1.34ml 1.34ml 4tk; 134mg+120,6mg 1.34ml 1.34ml 12tk; 134mg+120,6mg 1.34ml 1.34ml 60tk; 134mg+120,6mg 1.34ml 1.34ml 3tk; 134mg+120,6mg 1.34ml 1.34ml 120tk; 134mg+120,6mg 1.34ml 1.34ml 150tk; 134mg+120,6mg 1.34ml 1.34ml 90tk; 134mg+120,6mg 1.34ml 1.34ml 24tk

Eesti - eesti - Ravimiamet

rivopharm limited - sertraliin - õhukese polümeerikattega tablett - 100mg 100tk; 100mg 20tk; 100mg 50tk; 100mg 42tk; 100mg 98tk; 100mg 28tk